IS IL-6 Receptor blockade (Tocilizumab) beneficial or detrimental to pig-to-baboon organ Xenotransplantation?
The IL-6/IL-6 receptor-α (IL-6Rα)/STAT3 pathway plays an important role in inflammation. Anti-human IL-6Rα blockade by Tocilizumab (TCZ) has been used in pig-to-baboon organ xenotransplantation models, but whether it is beneficial remains uncertain. After xenotransplantation, there were significant increases in both baboon and pig IL-6 in the baboon serum, especially in baboons that received TCZ before xenotransplantation. In vitro observations demonstrated that human, baboon, and pig IL-6 can activate the IL-6/IL-6Rα/STAT3 pathway in human, baboon, and pig cells. Activation of the IL-6/IL-6Rα/STAT3 pathway was blocked by TCZ in human and baboon cells, but not in pig cells (i.e., pig IL-6R). Siltuximab (human IL-6 inhibitor) bound to both human and baboon, but not pig, IL-6, and suppressed activation of the IL-6/IL-6Rα/STAT3 pathway. These results indicate that TCZ and Siltuximab do not cross-react with pig IL-6R and pig IL-6, respectively. Rapamycin partially inhibited human, baboon, and pig IL-6/IL-6Rα/STAT3 pathways, and suppressed inflammatory gene expression. TCZ treatment increased serum IL-6 because it could no longer bind to baboon IL-6Rα. We suggest that increased serum IL-6 may be detrimental to the pig xenograft because it is likely to bind to pig IL-6R, resulting in activation of pig cells.